Stem definition | Drug id | CAS RN |
---|---|---|
serotonin (5-HT1) receptor agonists, sumatriptan derivatives | 1251 | 158747-02-5 |
Dose | Unit | Route |
---|---|---|
2.50 | mg | O |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 6 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 0.44 ยตM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BA (Bioavailability) | 27 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Vd (Volume of distribution) | 3.60 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 2.50 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 0.85 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 24 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
Nov. 8, 2001 | FDA | ENDO PHARMS |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Neovascularisation | 154.32 | 29.56 | 27 | 1623 | 986 | 50602488 |
Migraine | 135.26 | 29.56 | 60 | 1590 | 75220 | 50528254 |
Paradoxical drug reaction | 119.82 | 29.56 | 27 | 1623 | 3620 | 50599854 |
Anuria | 89.66 | 29.56 | 27 | 1623 | 11217 | 50592257 |
Extrapyramidal disorder | 88.45 | 29.56 | 27 | 1623 | 11743 | 50591731 |
Drug ineffective for unapproved indication | 80.19 | 29.56 | 29 | 1621 | 21252 | 50582222 |
Lichen planus | 50.82 | 29.56 | 12 | 1638 | 1967 | 50601507 |
Dyspepsia | 48.22 | 29.56 | 30 | 1620 | 74067 | 50529407 |
Cough | 33.23 | 29.56 | 40 | 1610 | 241224 | 50362250 |
Weight decreased | 32.65 | 29.56 | 38 | 1612 | 221207 | 50382267 |
None
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Neovascularisation | 160.41 | 43.49 | 27 | 1515 | 1076 | 64496114 |
Migraine | 124.12 | 43.49 | 49 | 1493 | 62628 | 64434562 |
Paradoxical drug reaction | 114.26 | 43.49 | 27 | 1515 | 6093 | 64491097 |
Anuria | 84.03 | 43.49 | 27 | 1515 | 18937 | 64478253 |
Extrapyramidal disorder | 83.22 | 43.49 | 27 | 1515 | 19525 | 64477665 |
Drug ineffective for unapproved indication | 74.56 | 43.49 | 28 | 1514 | 31105 | 64466085 |
Dyspepsia | 60.24 | 43.49 | 32 | 1510 | 80280 | 64416910 |
None
Source | Code | Description |
---|---|---|
ATC | N02CC07 | NERVOUS SYSTEM ANALGESICS ANTIMIGRAINE PREPARATIONS Selective serotonin (5HT1) agonists |
MeSH PA | D018377 | Neurotransmitter Agents |
MeSH PA | D018490 | Serotonin Agents |
MeSH PA | D017366 | Serotonin Receptor Agonists |
FDA MoA | N0000175763 | Serotonin 1b Receptor Agonists |
FDA MoA | N0000175764 | Serotonin 1d Receptor Agonists |
FDA EPC | N0000175765 | Serotonin-1b and Serotonin-1d Receptor Agonist |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Migraine | indication | 37796009 | DOID:6364 |
Hypercholesterolemia | contraindication | 13644009 | |
Coronary artery spasm | contraindication | 23687008 | DOID:11840 |
Hypertensive disorder | contraindication | 38341003 | DOID:10763 |
Conduction disorder of the heart | contraindication | 44808001 | |
Hemiplegic migraine | contraindication | 59292006 | |
Diabetes mellitus | contraindication | 73211009 | DOID:9351 |
Vascular insufficiency of intestine | contraindication | 82196007 | |
Prinzmetal angina | contraindication | 87343002 | |
Angina pectoris | contraindication | 194828000 | |
Cerebrovascular accident | contraindication | 230690007 | |
Transient ischemic attack | contraindication | 266257000 | DOID:224 |
Raynaud's phenomenon | contraindication | 266261006 | |
Serotonin syndrome | contraindication | 371089000 | |
Cardiovascular event risk | contraindication | 395112001 | |
Peripheral vascular disease | contraindication | 400047006 | |
Disorder of coronary artery | contraindication | 414024009 | |
Myocardial ischemia | contraindication | 414795007 | DOID:3393 |
Obesity | contraindication | 414916001 | DOID:9970 |
Hypertensive urgency | contraindication | 443482000 |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 12.14 | acidic |
pKa2 | 12.79 | acidic |
pKa3 | 10.16 | Basic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
5-hydroxytryptamine receptor 1B | GPCR | AGONIST | Ki | 7.99 | CHEMBL | CHEMBL | |||
5-hydroxytryptamine receptor 1D | GPCR | AGONIST | Ki | 8.36 | CHEMBL | CHEMBL | |||
5-hydroxytryptamine receptor 1A | GPCR | Ki | 7.21 | CHEMBL |
ID | Source |
---|---|
4021297 | VUID |
N0000148734 | NUI |
D04264 | KEGG_DRUG |
158930-17-7 | SECONDARY_CAS_RN |
4021297 | VANDF |
C0754647 | UMLSCUI |
CHEBI:134991 | CHEBI |
CHEMBL1279 | ChEMBL_ID |
DB00998 | DRUGBANK_ID |
CHEMBL2138684 | ChEMBL_ID |
CHEMBL1200371 | ChEMBL_ID |
C108128 | MESH_SUPPLEMENTAL_RECORD_UI |
77992 | PUBCHEM_CID |
7191 | IUPHAR_LIGAND_ID |
7661 | INN_ID |
H82Q2D5WA7 | UNII |
228783 | RXNORM |
16207 | MMSL |
239641 | MMSL |
d04776 | MMSL |
009509 | NDDF |
009510 | NDDF |
370214004 | SNOMEDCT_US |
411990007 | SNOMEDCT_US |
767324002 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Frovatriptan | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-3140 | TABLET, FILM COATED | 2.50 mg | ORAL | ANDA | 26 sections |
Frovatriptan Succinate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0603-3718 | TABLET, FILM COATED | 2.50 mg | ORAL | NDA | 25 sections |
FROVA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16590-396 | TABLET, FILM COATED | 2.50 mg | ORAL | NDA | 25 sections |
FROVA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63481-025 | TABLET, FILM COATED | 2.50 mg | ORAL | NDA | 25 sections |
frovatriptan succinate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 68462-694 | TABLET, FILM COATED | 2.50 mg | ORAL | ANDA | 25 sections |
Frovatriptan | HUMAN PRESCRIPTION DRUG LABEL | 1 | 69238-1539 | TABLET, FILM COATED | 2.50 mg | ORAL | ANDA | 25 sections |